Latest Dupixent (dupilumab) and Itepekimab data at ERS highlight scientific innovation and leadership in respiratory disease

20 abstracts, including 4 oral presentations, provide novel treatment insights for chronic obstructive pulmonary disease (COPD), asthma and chronic rhinosinusitis with nasal polyposis (CRSwNP)

Data from pivotal Phase 3 studies of Dupixent in COPD confirm reduction in exacerbations and improvement in lung function compared to placebo, and provide new assessments of health-related quality of life in patient subgroups